Oslo, Norway, 14 January 2013: Photocure ASA has today purchased 2200 own shares in the market at an average price of NOK 39.50 per share. After this transaction, Photocure owns a total of 183,958 own shares.

The transaction is part of share repurchase program, authorized by the Annual General Meeting held on 10 May 2012 in connection with employee share purchase program. In accordance with the resolution, the Board of Directors of Photocure ASA has decided to acquire up to 100 000 shares. For more details on the program, please download the minutes under Investor relations/Reports and presentations at www.photocure.com.

For further information contact:
Photocure Erik Dahl, CFO
Tel: + 47 450 55 000, Email: ed@photocure.com

About Photocure

Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com.

Photodynamic technology is the application of a photosensitizer followed by exposure to light for activation.

HPV: human papilloma virus Photocure Technology is Photocure's specifically designed photosensitizers combined with the exposure to light for diagnosis and/or treatment of specific conditions.

All trademarks mentioned in this release are protected by law and registered trademarks of Photocure.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act).
distributed by